Cerebrolysin dosing & administration

Gavrilova SI, Alvarez A · 2021

After 30 years of clinical use, Cerebrolysin has proven to be both safe and effective for Alzheimer's patients, especially when combined with standard brain-boosting drugs like cholinesterase inhibitors. The peptide works through multiple pathways—like a multi-tool rather than a single fix—making it one of the most promising brain protective treatments available.

Mureșanu DF, Livinț Popa L, Chira D et al. · 2022

Cerebrolysin's ability to repair damaged brain tissue works in both the immediate aftermath of a stroke and weeks or months later during recovery. The peptide's multi-target action on brain repair pathways makes it uniquely effective at restoring lost function while maintaining a strong safety record.

Kojder K, Jarosz K, Bosiacki M et al. · 2023

When researchers looked at all available studies of Cerebrolysin in patients with catastrophic brain bleeding, the evidence suggested the drug could save lives by reducing mortality. However, the field still needs larger, carefully controlled studies to confirm this life-saving potential.

Fiani B, Chacon D, Jarrah R et al. · 2021

Newborns with oxygen-starved brains can be treated with Cerebrolysin for up to 6 months after birth, and injections twice weekly helped babies recover better motor control and speech ability. This rare 6-month window offers hope for protecting developing brains from permanent damage.

Al-Kuraishy HM, Al-Gareeb AI, Zekry SH et al. · 2025

Cerebrolysin's brain-protecting peptides work against three major causes of vascular dementia: inflammation in the brain, damage to the blood-brain barrier, and chronic blood flow shortages. This triple action makes it a promising strategy for both preventing and treating this common form of dementia.

Guekht AB et al. · 2011

Vascular dementia trial used intravenous Cerebrolysin 20 mL once daily, infused over 2 treatment cycles, showing clinical improvement versus placebo.

2012

Acute ischemic stroke protocols used 30 mL Cerebrolysin diluted to 100 mL saline, infused once daily over ~30 minutes for 10 days. General stroke and TBI practice uses 10-50 mL IV daily for 10-21 days, with 5-10 mL IM used for lower-dose courses.

Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K · 2023

Cochrane review. Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, widely used for acute ischaemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries. Seven RCTs (1773 participants); risk of bias unclear or high across most domains, three multicentre studies supported by the manufacturer. Little to no difference in total adverse events, but a probable increase in non-fatal serious adverse events.

Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L · 2019

Cochrane review. Six randomised trials, 597 participants total, conducted in China, Russia and Romania; beneficial effect on cognition and global function but very low-quality evidence, high risk of bias in the included papers, and all studies with declared funding were industry-supported. No difference in rates of adverse effects.

EVER Neuro Pharma GmbH · 2023

Manufacturer handling and prescribing handbook. Daily dose by disorder: stroke 20-50 mL for 10-21 days; traumatic brain injury 20-50 mL for 7-30 days; Alzheimer's disease and vascular dementia 10-30 mL, one cycle of 5 days weekly for 4 weeks, 2-4 cycles per year. Routes: IV infusion 10-50 mL diluted to at least 100 mL and infused over 15-60 minutes; IV injection up to 10 mL undiluted over 3 minutes; IM injection up to 5 mL. Morning administration preferred because the infusion is stimulating and may cause excitability. Fever occurs in rare cases and is linked to rate of administration and to microbial growth in an opened ampoule. Contraindications: hypersensitivity, status epilepticus, severe renal failure. One mL contains 215.2 mg of Cerebrolysin concentrate; marketing authorisation holder EVER Neuro Pharma GmbH, Unterach, Austria.

EVER Neuro Pharma GmbH (registered product information) · 2024

Registered product information. One mL contains 215.2 mg of Cerebrolysin concentrate, a peptide complex from pig brain. Doses by indication: Alzheimer's disease 10-30 mL, ischaemic stroke 10-50 mL acute and 5-30 mL in recovery, traumatic brain injury 5-50 mL, cognitive impairment 5-30 mL. IM up to 5 mL, IV bolus up to 10 mL, 10-50 mL only by slow IV infusion after dilution over 15-60 minutes; rapid injection can cause heat sensation, sweating and dizziness. Course 10-20 days daily, repeat courses every 3-6 months. Contraindications: hypersensitivity, severe renal failure, status epilepticus. Adverse reactions: rare agitation, confusion, insomnia and dizziness; very rare hypersensitivity and allergic reactions, fever, dyspnoea, collapsoid state, tachycardia, arrhythmia, dyspepsia, nausea, vomiting, diarrhoea, constipation, and injection-site erythema, burning and pruritus.

Fiani B, Covarrubias C, Wong A, Doan T, Reardon T, Nikolaidis D, Sarno E · 2021

Cerebrolysin is not approved for use in the USA but is used clinically in over 50 countries worldwide. The review outlines the molecular signaling pathways through which Cerebrolysin acts in the central nervous system, and reports that it is generally safe for human use with inconsistent efficacy results across clinical studies.

Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A · 2016

30 mL/day Cerebrolysin for 21 days started 24-72 h after stroke, alongside standardised rehabilitation, produced a large superiority over placebo on upper-extremity motor function (Action Research Arm Test) at day 90 and a small-to-medium superiority on global status across 12 outcome scales. Safety was comparable with placebo.

Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, Sandesc D, von Steinbüchel N, Strilciuc S, Vos PE, von Wild K, Muresanu D · 2021

Two phase IIIb/IV randomised, double-blind, placebo-controlled trials in moderate-severe TBI (GCS 6-12), 185 patients, using 50 mL/day for ten days followed by two cycles of 10 mL/day for 10 days. The multidimensional functional and neuropsychological outcome ensemble favoured Cerebrolysin at day 30 and day 90, with comparable safety and tolerability to placebo.

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, Linares C, Granizo E, García-Fantini M, Baurecht W, Doppler E, Moessler H · 2011

Randomised double-blind trial of Cerebrolysin 10 mL (n=64), donepezil 10 mg (n=66) and the combination (n=67) in mild-to-moderate Alzheimer's disease. Cognitive performance improved in all three arms with the best scores in the combination group at every study visit; global outcome favoured Cerebrolysin and the combination. The combination of neurotrophic and cholinergic treatment was safe.

Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A · 2023

Review of five neurotrophic factors — NGF, IGF-1, BDNF, VEGF and TNF-alpha — and of Cerebrolysin, which resembles their activities and modulates the expression of endogenous neurotrophic factors. Covers the effects of these factors and of Cerebrolysin on neuroplasticity, neurogenesis, angiogenesis and inflammation in dementia, stroke and TBI.

Avci S, Gunaydin S, Ari NS, Karaca Sulukoglu E, Polat OE, Gecili I, Yeni Y, Yilmaz A, Genc S, Hacimuftuoglu A, Yildirim S, Mokresh MY, Findik DG, Tsatsakis A, Margina D, Tsarouhas K, Wallace DR, Taghizadehghalehjoughi A · 2022

Cerebrolysin is described as a mixture of enzymatically treated peptides derived from pig brain including neurotrophic factors such as BDNF, GDNF, NGF and CNTF. In primary cortical neuron culture exposed to glutamate, cerebrolysin protected neurons by lowering synaptic-cleft glutamate via the glutamate transporters EAAT1 and EAAT2, raising antioxidant activity and reducing inflammatory cytokines.

Marghani BH, Rezk S, Ateya AI, Alotaibi BS, Othman BH, Sayed SM, Alshehri MA, Shukry M, Mansour MM · 2023

In a mouse forebrain ischaemia-reperfusion model, cerebrolysin given 3 h after reperfusion improved neurological recovery, reduced apoptotic neuronal death and inhibited reactive microglial and astrocyte activation, reducing TLR/NF-kB/cytokine signalling while activating the Keap1/Nrf2 antioxidant pathway.

Lu W, Zhu Z, Shi D, Li X, Luo J, Liao X · 2022

Cerebrolysin decreased TNF-alpha, IL-1beta, IL-6 and NF-kB after traumatic brain injury and significantly lowered Toll-like receptor 2 and Toll-like receptor 4 levels, reducing hippocampal neuronal apoptosis. The same reduction in inflammatory mediators was seen in TBI patients.

Karimian A, Abdolmaleki A, Asadi A, Zahri S, Ghanimi HA · 2025

Cerebrolysin improved functional outcomes and axonal regeneration after nerve injury and induced a shift in macrophage polarisation from the pro-inflammatory M1 phenotype to the pro-healing M2 phenotype. The review notes that Cerebrolysin crosses the blood-brain barrier and contains neuropeptides and growth factors from pig brain such as BDNF, NGF and GDNF.

Aguilar-Hernández L, Flores-Gómez GD, Nacher J, Morales-Medina JC, Flores G · 2025

Cerebrolysin limited age-related loss of dendritic spines and memory decline in mice. The mechanism is framed through BDNF acting on its tyrosine kinase B (TrkB) receptor and the downstream PI3K/Akt/CREB and ERK/MAPK signalling cascades, which drive spine morphogenesis, synaptic transmission and neurogenesis.

Trimmel H, Tauber W, Zikeli M · 2024

Case report of a fulminant, laboratory-confirmed anaphylactic reaction after intravenous cerebrolysin in an 85-year-old man with subacute stroke. The drug is described as obtained from highly purified porcine brain proteins by standardised enzymatic degradation, consisting of 25% low molecular weight peptides and free amino acids. Only rare cases of anaphylaxis to cerebrolysin have been published.

Anandan P, Rengarajan S, Venkatachalam S, Pattabi S, Jones S, Prabhu K, Krishna V, Prasanth K · 2024

States that Cerebrolysin, a peptidergic medication, is composed of 75% free amino acids and 25% low-molecular-weight peptides. In an oxidative-stress model of neuronal injury, cerebrolysin produced modest neuroprotection and upregulated BDNF and Neuregulin 1 expression.

Plosker GL, Gauthier S · 2009

Review of the parenterally administered porcine brain-derived peptide preparation in Alzheimer's disease and vascular dementia. Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) the most frequently reported adverse event.